The US Food and Drug Administration has approved the Portico with FlexNav (Abbott) transcatheter aortic valve replacement (TAVR) system for patients with “symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery,” the company announced recently. Portico is a self-expanding TAVR valve with leaflets that help provide optimal blood flow when…
Login in to view this article:
You need to be logged in to view the rest of this article. Don't have an account? Register for one below.
Subscribe
0 Comments
Oldest